Mineralys' lorundrostat lowers blood pressure in kidney disease patients in Phase 3 trial
MLYS•Lorundrostat significantly lowered blood pressure versus placebo in Mineralys Therapeutics' Phase 3 trial, with similar benefits in participants with or without chronic kidney disease. It also reduced a kidney-damage marker in participants with chronic kidney disease; the FDA is reviewing the drug for hypertension, with a target decision date of Dec. 22, 2026.
1. Trial results
Mineralys Therapeutics presented new results from its pivotal Phase 3 Launch-HTN trial at ASN Kidney Week on Oct. 22, 2026. Lorundrostat significantly lowered blood pressure versus placebo, with similar benefits in participants with or without chronic kidney disease.
2. Kidney marker and review
Among participants with chronic kidney disease, treatment reduced a marker of kidney damage and had an acceptable safety profile. The FDA is reviewing lorundrostat for use alongside other antihypertensive drugs, with a target decision date of Dec. 22, 2026.
